Alembic Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2025, recommended Final Dividend of 11 per equity share.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals announced audited results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations rose modestly to Rs. 6,672.08 crores from Rs. 6,228.63 crores (~7% growth), while consolidated profit after tax fell to Rs. 582.01 crores from Rs. 615.82 crores. On a standalone basis, revenue grew to Rs. 6,032.63 crores but profit after tax declined sharply to Rs. 503.12 crores from Rs. 666.48 crores (~24.5% drop). EPS stood at Rs. 29.68 (consolidated) and Rs. 25.60 (standalone). The Board recommended a final dividend of Rs. 11 per share (550%), unchanged from the previous year. An exceptional item of Rs. 12.87 crores was recognized as net income from a Sikkim flood-related insurance claim.
Dividend maintained at the same level as last year provides steady income for shareholders, but the significant drop in standalone profits and compression in operating margins (15.74% vs 17.53%) may weigh on the stock. Higher borrowings pushed the debt-equity ratio from 0.09 to 0.23, worth monitoring.